TCT 2024: Valve under-expansion plagues Boston Scientific's head-to-head TAVR trial

WASHINGTON, D.C.—Boston Scientific’s long-awaited transcatheter aortic heart valve missed its mark in a head-to-head study aimed at bringing the implant to the U.S.—but the company believes ... Read More

Boston Scientific’s Acurate Neo2 inferior to rival TAVR valves in study - Yahoo Finance

Boston Scientific’s Acurate Neo2 transcatheter aortic replacement valve (TAVR) failed to meet its primary endpoint of noninferiority in a head-to-head comparison with valves from Edwards ... Read More

Boston Scientific presents ACURATE neo2 data at TCT 2024

Boston Scientific (BSX) Corporation announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2 Aortic Valve System in the treatment of ... Read More

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024 - Yahoo Finance

Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the ... Read More

Underexpanded Acurate Valves Come With Higher Stroke Risk, Study Confirms

Though the Acurate neo and neo2 valves are no longer available, there are lessons here for other self-expanding TAVI platforms. Read More

Boston Scientific’s TAVR hopes dashed again, as it pulls Acurate heart valves from global market

TCT 2024: Valve under-expansion plagues Boston Scientific's head-to-head TAVR trial However, the company did not see the same success in a recent clinical trial. Read More

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024 - Nasdaq

MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024/ PRNewswire/-- Boston Scientific Corporation today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated ... Read More